Mehmet Cilingiroglu: Navigating Anticoagulation Choices in Acute Coronary Syndrome PCI
Mehmet Cilingiroglu, Clinical Professor of Medicine/Cardiology at the University of Hawaii John A. Burns School of Medicine, Cardiologist at Hawaii Pacific Health, shared a post on LinkedIn:
“Anticoagulation During ACS-PCI:
Which Agent Should We Choose?
The 2025 ACC/AHA and 2023 ESC guidelines support unfractionated heparin (UFH) as the standard procedural anticoagulant for patients undergoing PCI for acute coronary syndromes.
Bivalirudin and enoxaparin are appropriate alternatives in selected patients, while argatroban is an option when heparin-induced thrombocytopenia is present.
Fondaparinux may be useful in NSTE-ACS before PCI but must never be used as the sole anticoagulant during PCI because of catheter thrombosis risk.
Careful assessment of bleeding risk, renal function, platelet counts, and appropriate anticoagulation monitoring is essential.
The best anticoagulant is not necessarily the newest or most expensive—it is the one supported by evidence and appropriate for the individual patient!”
Stay updated with Hemostasis today.
-
Nov 8, 2026, 14:06Shayan Mohammadmoradi: ZEUS Trial-Inflammation Reduction Without Fewer Cardiovascular Events
-
Nov 8, 2026, 14:05Kausik Ray: Plaque-Guided Care for Better Coronary Outcomes
-
Nov 8, 2026, 14:05Athira Elssa Johnson: Understanding Coronary Thrombosis and Its Risks
-
Nov 8, 2026, 14:04Sanjiv Beri: Blood Type Compatibility and the Balance of Giving and Receiving
-
Nov 8, 2026, 14:02Gabriela Hobbs: Recognizing Outstanding Abstract Achievements-ASH 2026
-
Nov 8, 2026, 12:22Marc Carrier: Advancing Catheter-Related Thrombosis Prevention Through Factor XI Inhibition
-
Nov 8, 2026, 11:56Why Genetic Predisposition Does Not Always Lead to Thrombosis – Stork Genetics
-
Nov 8, 2026, 11:45Sher-Lu Pai: Investigating Intracardiac Thrombosis and Its Management in Liver Transplantation
-
Nov 8, 2026, 07:16Gilberto de lima Lopes Junior: The Cardiovascular Consequences of Cancer in Younger Patients